Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and the best dose of uprosertib when given
together with dabrafenib and trametinib and to see how well they work in treating patients
with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with
dabrafenib and trametinib may be a better treatment for cancer.